Healios KK (TSE:4593) E10: 円-81.32 (As of Mar. 2026)


TSE:4593 Healios KK TSE:4593
53 GF Score
Price 円261.00
GF Value 円56.74
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK E10?

Healios KK TSE:4593 +1.95% 53 E10 is 円-81.32 as of Mar. 2026. GuruFocus rates TSE:4593 with a GF Score™ of 53/100 and a GF Value™ of 円56.74 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Healios KK's adjusted earnings per share data for the three months ended in Mar. 2026 was 円-27.650. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is 円-81.32 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-11), Healios KK's current stock price is 円261.00. Healios KK's E10 for the quarter that ended in Mar. 2026 was 円-81.32. Healios KK's Shiller PE Ratio of today is .


Healios KK  (TSE:4593) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Healios KK E10 Related Terms


Healios KK E10 Historical Data

* Premium members only.

The historical data trend for Healios KK's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK E10 Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -83.33 -84.81

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.49 -87.41 -86.43 -84.81 -81.32

TSE:4593 vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Healios KK's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Healios KK's Shiller PE Ratio falls into.


TSE:4593
53GF Score
Healios KK TSE:4593
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Healios KK's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-27.65/112.7000*112.7000
=-27.650

Current CPI (Mar. 2026) = 112.7000.

Healios KK Quarterly Data

per share eps CPI Adj_EPS
201606 -12.760 98.100 -14.659
201609 -11.120 98.000 -12.788
201612 -8.066 98.400 -9.238
201703 -12.800 98.100 -14.705
201706 4.016 98.500 4.595
201709 -19.620 98.800 -22.380
201712 -11.990 99.400 -13.594
201803 -11.240 99.200 -12.770
201806 -56.280 99.200 -63.939
201809 -14.923 99.900 -16.835
201812 -21.092 99.700 -23.842
201903 -19.020 99.700 -21.500
201906 -20.990 99.800 -23.703
201909 -20.000 100.100 -22.517
201912 -35.860 100.500 -40.213
202003 -24.620 100.300 -27.664
202006 -26.190 99.900 -29.546
202009 -27.330 99.900 -30.832
202012 -29.050 99.300 -32.970
202103 -25.090 99.900 -28.305
202106 -16.680 99.500 -18.893
202109 -34.850 100.100 -39.237
202112 -28.100 100.100 -31.637
202203 -26.480 101.100 -29.518
202206 -32.630 101.800 -36.124
202209 -12.310 103.100 -13.456
202212 -19.540 104.100 -21.154
202303 -11.510 104.400 -12.425
202306 -10.370 105.200 -11.109
202309 -9.990 106.200 -10.601
202312 -24.430 106.800 -25.780
202403 -29.050 107.200 -30.540
202406 -5.920 108.200 -6.166
202409 -17.000 108.900 -17.593
202412 3.220 110.700 3.278
202503 -26.720 111.100 -27.105
202506 -20.310 111.700 -20.492
202509 7.540 112.000 7.587
202512 12.890 113.000 12.856
202603 -27.650 112.700 -27.650

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of 円-81.32 mean?
Healios KK (TSE:4593) has a E10 of 円-81.32 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Healios KK and its competitors.
Is Healios KK's E10 too high?
Healios KK's current E10 is 円-81.32. Overall, Healios KK has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's E10 compare to VRTX and REGN?
Healios KK's E10 of 円-81.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Healios KK and its competitors. Healios KK's current E10 is 円-81.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円56.74, compared to a current price of 円261.00 — trading 360% above its estimated fair value. The current E10 is 円-81.32. Healios KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Healios KK (TSE:4593), the current E10 is 円-81.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (TSE:4593) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of 円261.00 is trading 360% above its estimated GF Value™ of 円56.74. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for TSE:4593:

  • E10: 円-81.32
  • GF Value™: 円56.74 vs. price of 円261.00 (360% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healios KK Business Description

Other Exchanges HLOSF:USA6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
53GF Score

Get the complete analysis for TSE:4593

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円261.00
Price
円56.74
GF Value